DDInter1853 DDInter1925
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of [vitamin A] (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities. It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles [A257474,A258185] and activates nuclear receptors to regulate epithelial cell growth and differentiation.[A257474,A257629,A257609] Tretinoin is given orally to treat acute promyelocytic leukemia and topically to treat skin conditions such as acne.[L45389,L34869,L45384]
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Tretinoin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Tretinoin {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Tretinoin {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Tretinoin {u} (Compound) upregulates {v} (Gene) ALAS1
ALAS1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Tretinoin {u} (Compound) downregulates {v} (Gene) NT5DC2
NT5DC2 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Tretinoin {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Isotretinoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Tretinoin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Tretinoin {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is regulated by {v} (Gene) BRAF
BRAF {u} (Gene) is bound by {v} (Compound) Vemurafenib
Tretinoin {u} (Compound) upregulates {v} (Gene) ARHGEF2
ARHGEF2 {u} (Gene) is upregulated by {v} (Disease) melanoma
melanoma {u} (Disease) is treated by {v} (Compound) Vemurafenib
Tretinoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Tretinoin (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Vemurafenib (Compound)
Tretinoin (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Vemurafenib (Compound)
Tretinoin (Compound) upregulates ALAS1 (Gene) and ALAS1 (Gene) is downregulated by Vemurafenib (Compound)
Tretinoin (Compound) downregulates NT5DC2 (Gene) and NT5DC2 (Gene) is downregulated by Vemurafenib (Compound)
Tretinoin (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Tretinoin (Compound) resembles Isotretinoin (Compound) and Iso
Tretinoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Tretinoin (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is regulated by BRAF (Gene) and BRAF (Gene) is bound by Vemurafenib (Compound)
Tretinoin (Compound) upregulates ARHGEF2 (Gene) and ARHGEF2 (Gene) is upregulated by melanoma (Disease) and melanoma (Disease) is treated by Vemurafenib (Compound)